[
    [
        {
            "time": "2021-11-21",
            "original_text": "基石药业-B：与恒瑞医药就CS1002达成在大中华地区的战略合作",
            "features": {
                "keywords": [
                    "基石药业",
                    "恒瑞医药",
                    "CS1002",
                    "战略合作",
                    "大中华地区"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "基石药业-B：与恒瑞医药就CS1002达成在大中华地区的战略合作",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-21",
            "original_text": "恒瑞医药携手基石药业布局重磅肿瘤药",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "基石药业",
                    "肿瘤药",
                    "布局"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药携手基石药业布局重磅肿瘤药",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-21",
            "original_text": "“药茅”又一大动作！斥巨资引进抗肿瘤药品",
            "features": {
                "keywords": [
                    "药茅",
                    "恒瑞医药",
                    "抗肿瘤药品",
                    "引进"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "“药茅”又一大动作！斥巨资引进抗肿瘤药品",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-21",
            "original_text": "2亿美金！基石药业与恒瑞医药强强联合，就抗CTLA-4单抗CS1002达成战略合作！",
            "features": {
                "keywords": [
                    "2亿美金",
                    "基石药业",
                    "恒瑞医药",
                    "CTLA-4",
                    "单抗",
                    "战略合作"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "2亿美金！基石药业与恒瑞医药强强联合，就抗CTLA-4单抗CS1002达成战略合作！",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 10,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-11-21",
            "original_text": "恒瑞医药引进基石药业抗CTLA-4单克隆抗体CS1002",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "基石药业",
                    "CTLA-4",
                    "单克隆抗体",
                    "引进"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药引进基石药业抗CTLA-4单克隆抗体CS1002",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-21",
            "original_text": "国金证券：维持恒瑞医药“买入”评级 与基石合作 加速创新转型",
            "features": {
                "keywords": [
                    "国金证券",
                    "恒瑞医药",
                    "买入评级",
                    "基石合作",
                    "创新转型"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国金证券：维持恒瑞医药“买入”评级 与基石合作 加速创新转型",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]